Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lisata Therapeutics, Inc.

NASDAQ: LSTA · Life Sciences · 5 alerts · CIK 320017

Share price
$1.09Close, Nov 16
Market cap
$11.8M
Shares outstanding
10.8MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lisata Therapeutics, Inc. filings on SEC EDGAR ↗

4:09 PM ET 10-Q
Financial Results

Lisata Therapeutics Q3 2026 Results: Net Loss of $6.79M, Loss Widens

Lisata Therapeutics reported a significant increase in total assets to $648.4 million following the acquisition of Marea, which added $292.9 million in intangible assets and $64.7 million in goodwill. The company recorded a net loss of $6.8 million for the third quarter of 2026, with research and development expenses increasing to $5.2 million as they advance their combined pipeline.

Key figure
Net loss $6.79M
6:08 AM ET 8-K/A
M&A Deal

Lisata Therapeutics M&A Deal with Marea Therapeutics, Inc.

Lisata Therapeutics filed an amendment to its previous 8-K to provide required audited financial statements and pro forma financial information following its completed acquisition of Marea Therapeutics, Inc. The filing includes combined financial statements for Marea and M2 Therapeutics for the years 2024 and 2025, as well as interim 2026 data.

Counterparty
Marea Therapeutics, Inc.
5:16 PM ET 8-K
Shareholder Meeting

Lisata Therapeutics Shareholder Meeting

Lisata Therapeutics held its 2026 Annual Meeting of Stockholders on November 9, 2026, where shareholders approved several key proposals. Most notably, stockholders approved the 2026 Equity Incentive Plan with an initial reserve of 44.76 million shares and the 2026 Employee Stock Purchase Plan with an initial reserve of 3.73 million shares.

4:26 PM ET 8-K
Leadership Change

Lisata Therapeutics Leadership Change

Lisata Therapeutics appointed Jeffrey Farrow to its Board of Directors as a Class III member and a member of the Audit Committee, effective October 13, 2026. The appointment expands the company's board from seven to eight members. Mr. Farrow is a veteran biopharmaceutical executive currently serving as CFO and Chief Strategy Officer of Tarsus Pharmaceuticals.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.